GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02321878

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

1,092

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Treatment-emergent AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02321878

Org study IDNN2211-4175

Secondary IDU1111-1157-6701WHO

Timeline

Milestones

Study start2014-12-15actual

Study first posted2014-12-22estimated

Primary completion2017-06-16actual

Study completion2017-06-16actual

Last update posted2017-09-01actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Male or female patients with T2DM who the physician has decided to start on treatment with Victoza® in combination with insulin or oral anti-diabetes drug (OAD) other than SU (Sulfonylurea) will be eligible for this study.

Inclusion criteria

•Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)

•Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)

•Male or female, no age limitation

Exclusion criteria

•Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772

•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

•Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Change in HbA1c (glycosylated haemoglobin)

Time frame:Week 0, week 52

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Number of AEs (adverse events)

Time frame:Week 0-52

Treatment-emergent AEs (any)

event count, event

Secondary/protocol endpoint

Number of adverse reactions (ARs)

Time frame:Week 0-52

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.